FDA Issues CRL for Glatiramer Acetate Depot for Relapsing Fo

The FDA has declined to approve glatiramer acetate (GA) depot in the treatment of relapsing types of multiple sclerosis (MS), issuing a complete response letter (CRL) for the long-acting, injectable form of GA.

Related Keywords

Mapi Pharma , National Multiple Sclerosis Society , Reuters , Consortium Of Multiple Sclerosis Centers Annual Meeting , National Harbor , Paper Texture , Araki Illustrations , National Multiple Sclerosis , Multiple Sclerosis Centers Annual Meeting , Expanded Disability Status Scale ,